Trial · NCT07229846
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
NCT07229846, Phase 2, Not yet recruiting, Yanqiao Zhang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation. Trials, record NCT07229846. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07229846
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
- NCT number
- NCT07229846
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Yanqiao Zhang
- Conditions
- Colorectal Cancer
- Interventions
- Aipalolitovorelizumab, XELOX + Bevacizumab, mFOLFOX + Bevacizumab, FOLFOXIRI + Bevacizumab, Oxaliplatin + Irinotecan + Capecitabine + Bevacizumab
- First posted
- 2025-11-17
- Last updated
- 2026-01-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate | 6 months | Defined as the proportion of patients who achieved complete response (CR) andpartial response (PR) according to RECIST v1.1. |
| Secondary | Progression Free Survival | 1 year | Defined as the time between signing the informed consent form to the disease progression (according to REClST v1.1 criteria) or death due to any cause |
| Secondary | Disease Control Rate | 6 months | Defined as the proportion of patients who achieved complete response (CR),. partiaresponse (PR), and stable disease (SD) according to RECIST V1.1. |
| Secondary | Duration of Response | 6 months | Defined as the time from response(when CR or PR is first diagnosed) to disease progression or death due to any cause. |
| Secondary | Overall survival | 2 years | Defined as the time between signing the informed consent form to death due tovarious causes. |
| Secondary | Safety | 6 months | Use NCI-CTCAE version 5.0 for classification and grading |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07229846
GET https://conductscience.org/api/trials/v1/NCT07229846/registered